+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gadopentetate Dimeglumine Market - Global Forecast 2026-2032- Product Image
Gadopentetate Dimeglumine Market - Global Forecast 2026-2032- Product Image
Sale

Gadopentetate Dimeglumine Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6129142
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gadopentetate Dimeglumine Market is projected to reach USD 623.65 Million in 2026. It is expected to continue growing at a CAGR of 2.99%, reaching USD 742.84 Million by 2032.

Gadopentetate Dimeglumine: Clinical Context and Executive Summary

Gadopentetate dimeglumine is a gadolinium-based contrast agent historically used to enhance magnetic resonance imaging (MRI), particularly where improved visualization of vascularized tissue and abnormalities is clinically useful. Its role must be assessed within the broader evolution of MRI protocols, contrast-agent safety practices, regulatory requirements, and the availability of newer diagnostic alternatives. Clinical decisions depend on the indication, patient characteristics, renal function, institutional protocols, and applicable labeling rather than on contrast use alone.

MRI Protocols and Contrast-Agent Governance Are Reshaping the Landscape

The landscape is being transformed by more selective use of contrast-enhanced MRI, stronger screening for renal impairment, documentation of prior contrast reactions, and standardized informed-consent processes. Imaging departments are also emphasizing dose discipline, product traceability, emergency preparedness, and consistent interpretation standards. These changes place greater importance on evidence-based patient selection and operational controls, while the continued development of noncontrast MRI techniques and alternative gadolinium agents increases the need to define where gadopentetate dimeglumine remains clinically appropriate.

Artificial Intelligence Is Improving MRI Workflow, Not Replacing Clinical Judgment

Artificial intelligence is affecting MRI through protocol optimization, image reconstruction, motion correction, workflow prioritization, and decision support. These applications can help reduce scan time, improve image consistency, and support radiologist review, but their value depends on representative validation, transparent performance monitoring, cybersecurity, and integration with existing clinical systems. For gadopentetate dimeglumine, AI may help identify examinations that are likely to benefit from enhancement or flag image-quality issues, yet the decision to administer contrast remains a clinician-led assessment incorporating safety, indication, and patient-specific factors.

Regional Insights: Regulation, Access, and MRI Infrastructure Shape Use

North America generally combines advanced MRI infrastructure with stringent safety documentation and established oversight of contrast agents. Europe places strong emphasis on pharmacovigilance, renal-risk management, environmental considerations, and harmonized clinical guidance. Asia-Pacific presents substantial variation, ranging from highly developed imaging systems to rapidly expanding capacity, with procurement, training, and regulatory access influencing practice. Latin America is shaped by uneven availability of MRI services, public-private differences, and import or reimbursement conditions. In the Middle East, tertiary-care investment and referral-center concentration support advanced imaging, while access differs across countries. Africa faces broader constraints in equipment availability, maintenance, specialist staffing, and supply continuity, making protocol standardization and workforce development particularly important.

Group Insights: Multilateral and Economic Blocs Create Different Operating Conditions

ASEAN markets reflect diverse regulatory systems, healthcare financing models, and levels of imaging capacity, so regional cooperation and local registration requirements both matter. BRICS members combine large and varied healthcare systems, with domestic manufacturing, procurement policy, and unequal access influencing contrast-agent practice. The European Union benefits from shared regulatory structures while retaining differences in reimbursement and service delivery. G7 countries typically have mature MRI governance, strong safety surveillance, and greater adoption of workflow technologies. GCC states often have concentrated, well-equipped hospital networks alongside reliance on specialized imports and international expertise. NATO members span multiple health systems, but common preparedness, procurement, and interoperability considerations can support more resilient diagnostic supply chains.

Country Insights: Diverse Clinical and Regulatory Priorities Across Key Markets

Australia emphasizes evidence-based imaging, safety screening, and geographically responsive service delivery. Brazil and Mexico must address regional disparities in MRI access, procurement complexity, and specialist availability. Canada and the United States operate extensive imaging networks with strong attention to labeling, renal safety, documentation, and utilization management. China and India combine expanding diagnostic capacity with substantial variation between metropolitan and less-served areas. Japan and South Korea maintain technologically advanced imaging environments with detailed clinical and regulatory oversight. France, Germany, Italy, Spain, and the United Kingdom apply structured healthcare and safety frameworks, while reimbursement pathways and institutional protocols differ. Russia’s imaging environment is influenced by regulatory conditions, supply resilience, and uneven access across regions. Across all countries, appropriate use depends on approved indications, local guidance, patient risk assessment, and reliable post-administration monitoring.

Actions for Leaders: Strengthen Safety, Evidence, and Operational Resilience

Industry leaders should define clear clinical-use criteria, reinforce renal-function and hypersensitivity screening, and maintain documented protocols for dosing, administration, observation, and adverse-event response. They should monitor regulatory updates, environmental expectations, and local labeling across jurisdictions rather than assuming that practices are interchangeable. Investments in MRI workflow integration, staff training, inventory traceability, and supply-continuity planning can improve reliability. Organizations evaluating AI should require clinically relevant validation, bias assessment, human oversight, and ongoing monitoring. Comparative evidence should be interpreted in the context of indication, patient risk, image quality, and institutional capability-not isolated technology claims.

Research Methodology: Evidence-Based Review of Clinical and Operating Conditions

This executive summary uses the supplied market definition-gadopentetate dimeglumine-and synthesizes established considerations from clinical imaging practice, contrast-agent safety principles, regulatory governance, healthcare infrastructure, and regional operating conditions. The assessment is qualitative and deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis. Regional, group, and country observations are framed as contextual comparisons; product use should be verified against current national labeling, professional guidance, institutional policy, and patient-specific clinical information.

Conclusion: Disciplined Selection Will Define the Role of Gadopentetate Dimeglumine

Gadopentetate dimeglumine should be evaluated as part of a changing MRI ecosystem in which safety governance, protocol efficiency, noncontrast capabilities, alternative agents, and AI-supported workflows increasingly influence practice. Regional and country differences in infrastructure, regulation, reimbursement, and specialist access remain material. The most durable approach is to combine clinically justified contrast use with rigorous screening, trained personnel, validated imaging protocols, responsible technology adoption, and continuous review of current evidence and applicable requirements.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gadopentetate Dimeglumine Market, by Form
7.1. Introduction
7.2. Pre Filled Syringes
7.3. Vials
7.3.1. Multi Dose Vials
7.3.2. Single Dose Vials
8. Gadopentetate Dimeglumine Market, by Application
8.1. Introduction
8.2. Cardiovascular System
8.2.1. Morphological Imaging
8.2.2. Perfusion Imaging
8.3. Central Nervous System
8.3.1. Brain Imaging
8.3.2. Spinal Cord Imaging
8.4. Musculoskeletal System
8.4.1. Bone Imaging
8.4.2. Joint Imaging
8.4.3. Soft Tissue Imaging
8.5. Oncology
8.5.1. Metastasis Imaging
8.5.2. Tumor Characterization
8.5.3. Tumor Detection
9. Gadopentetate Dimeglumine Market, by End User
9.1. Introduction
9.2. Academic And Research Institutes
9.3. Ambulatory Care Facilities
9.4. Diagnostic Centers
9.4.1. Multi Specialty Diagnostics
9.4.2. Standalone Imaging Centers
9.5. Hospitals
9.5.1. Private Hospitals
9.5.2. Public Hospitals
10. Gadopentetate Dimeglumine Market, by Distribution Channel
10.1. Introduction
10.2. Direct Sales
10.3. Distributor Sales
10.4. Online Sales
11. Gadopentetate Dimeglumine Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Gadopentetate Dimeglumine Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Gadopentetate Dimeglumine Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Accord Healthcare Limited
15.2. Bayer AG
15.3. Beijing Beilu Pharmaceutical Co., Ltd.
15.4. Bracco Imaging S.p.A.
15.5. China National Pharmaceutical Group
15.6. Chongqing Pharmaceutical (Group) Co., Ltd.
15.7. Dr. Reddy's Laboratories Limited
15.8. GE HealthCare Technologies, Inc.
15.9. Guerbet S.A.
15.10. Hengrui Medicine Co., Ltd.
15.11. Jodas Expoim Pvt. Ltd.
15.12. Jubilant Pharmova Limited
15.13. Laksh Fine Chem Pvt. Ltd.
15.14. Lantheus Holdings, Inc.
15.15. Mallinckrodt plc
15.16. Sagent Pharmaceuticals, Inc.
15.17. Sanochemia Pharmazeutika AG
15.18. Shanghai Bracco Sine Pharmaceutical Corp., Ltd.
15.19. Zhejiang Hisun Pharmaceutical Co., Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Gadopentetate Dimeglumine Market, Years Considered for the Study
FIGURE 2. Global Gadopentetate Dimeglumine Market, Research Design
FIGURE 3. Global Gadopentetate Dimeglumine Market, Research Framework
FIGURE 4. Global Gadopentetate Dimeglumine Market, Data Triangulation
FIGURE 5. Global Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gadopentetate Dimeglumine Market Size, by Form, 2025 vs 2032 (%)
FIGURE 7. Global Gadopentetate Dimeglumine Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gadopentetate Dimeglumine Market Size, by Application, 2025 vs 2032 (%)
FIGURE 9. Global Gadopentetate Dimeglumine Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gadopentetate Dimeglumine Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Gadopentetate Dimeglumine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gadopentetate Dimeglumine Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Gadopentetate Dimeglumine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gadopentetate Dimeglumine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Gadopentetate Dimeglumine Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Gadopentetate Dimeglumine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Gadopentetate Dimeglumine Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Gadopentetate Dimeglumine Market Segmentation & Coverage
TABLE 2. Global Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 4. Global Pre Filled Syringes Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Pre Filled Syringes Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Pre Filled Syringes Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Vials Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Vials Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Vials Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Multi Dose Vials Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Multi Dose Vials Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Multi Dose Vials Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Single Dose Vials Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Single Dose Vials Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Single Dose Vials Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 17. Global Cardiovascular System Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Cardiovascular System Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Cardiovascular System Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Morphological Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Morphological Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Morphological Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Perfusion Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Perfusion Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Perfusion Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Brain Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Brain Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Brain Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Spinal Cord Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Spinal Cord Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Spinal Cord Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Musculoskeletal System Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Musculoskeletal System Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Musculoskeletal System Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Bone Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Bone Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Bone Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Joint Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Joint Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Joint Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Soft Tissue Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Soft Tissue Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Soft Tissue Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Metastasis Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Metastasis Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Metastasis Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Tumor Characterization Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Tumor Characterization Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Tumor Characterization Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Tumor Detection Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Tumor Detection Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Tumor Detection Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 60. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Ambulatory Care Facilities Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Ambulatory Care Facilities Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Ambulatory Care Facilities Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Multi Specialty Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Multi Specialty Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Multi Specialty Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Standalone Imaging Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Standalone Imaging Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Standalone Imaging Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Global Direct Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Direct Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Direct Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Distributor Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Distributor Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Distributor Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Online Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Online Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Online Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. North America Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. North America Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 109. North America Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 110. North America Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 111. North America Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 112. North America Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 113. North America Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 114. North America Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 115. North America Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. North America Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 117. North America Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 118. North America Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. Latin America Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Latin America Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 121. Latin America Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 122. Latin America Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 123. Latin America Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 124. Latin America Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 125. Latin America Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 126. Latin America Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 127. Latin America Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Latin America Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 129. Latin America Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 130. Latin America Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. Europe Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Europe Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 133. Europe Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 134. Europe Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 135. Europe Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 136. Europe Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 137. Europe Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 138. Europe Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 139. Europe Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Europe Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 141. Europe Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 142. Europe Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Middle East Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Middle East Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 145. Middle East Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 146. Middle East Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 147. Middle East Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 148. Middle East Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 149. Middle East Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 150. Middle East Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 151. Middle East Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. Middle East Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 153. Middle East Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 154. Middle East Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Africa Gadopentetate Dimeglumine Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Africa Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 157. Africa Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 158. Africa Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 159. Africa Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 160. Africa Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 161. Africa Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 162. Africa Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 163. Africa Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. Africa Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 165. Africa Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 166. Africa Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 167. Global Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. ASEAN Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. ASEAN Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 170. ASEAN Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 171. ASEAN Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. ASEAN Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 173. ASEAN Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 174. ASEAN Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 175. ASEAN Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 176. ASEAN Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. ASEAN Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 178. ASEAN Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 179. ASEAN Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. GCC Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. GCC Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 182. GCC Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 183. GCC Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 184. GCC Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 185. GCC Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 186. GCC Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 187. GCC Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 188. GCC Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. GCC Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 190. GCC Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 191. GCC Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. European Union Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. European Union Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 194. European Union Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 195. European Union Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 196. European Union Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 197. European Union Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 198. European Union Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 199. European Union Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 200. European Union Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. European Union Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 202. European Union Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 203. European Union Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. BRICS Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 205. BRICS Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 206. BRICS Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 207. BRICS Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 208. BRICS Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 209. BRICS Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 210. BRICS Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 211. BRICS Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 212. BRICS Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. BRICS Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 214. BRICS Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 215. BRICS Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. G7 Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 217. G7 Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 218. G7 Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 219. G7 Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 220. G7 Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 221. G7 Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 222. G7 Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 223. G7 Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 224. G7 Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. G7 Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 226. G7 Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 227. G7 Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. NATO Gadopentetate Dimeglumine Market Size, by Group, 2017-2032 (USD Million)
TABLE 229. NATO Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 230. NATO Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 231. NATO Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 232. NATO Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 233. NATO Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 234. NATO Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 235. NATO Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 236. NATO Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. NATO Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 238. NATO Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 239. NATO Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. Global Gadopentetate Dimeglumine Market Size, by Country, 2017-2032 (USD Million)
TABLE 241. United States Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 242. United States Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 243. United States Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 244. United States Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 245. United States Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 246. United States Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 247. United States Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 248. United States Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 249. United States Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. United States Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 251. United States Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 252. United States Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 253. Canada Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 254. Canada Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 255. Canada Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 256. Canada Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 257. Canada Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 258. Canada Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 259. Canada Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 260. Canada Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 261. Canada Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Canada Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 263. Canada Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 264. Canada Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 265. Mexico Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 266. Mexico Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 267. Mexico Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 268. Mexico Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 269. Mexico Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 270. Mexico Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 271. Mexico Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 272. Mexico Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 273. Mexico Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 274. Mexico Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 275. Mexico Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 276. Mexico Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Brazil Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 278. Brazil Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 279. Brazil Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 280. Brazil Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 281. Brazil Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 282. Brazil Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 283. Brazil Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 284. Brazil Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 285. Brazil Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. Brazil Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 287. Brazil Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 288. Brazil Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 289. United Kingdom Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 290. United Kingdom Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 291. United Kingdom Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 292. United Kingdom Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 293. United Kingdom Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 294. United Kingdom Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 295. United Kingdom Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 296. United Kingdom Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 297. United Kingdom Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. United Kingdom Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 299. United Kingdom Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 300. United Kingdom Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 301. Germany Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 302. Germany Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 303. Germany Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 304. Germany Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 305. Germany Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 306. Germany Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 307. Germany Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 308. Germany Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 309. Germany Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 310. Germany Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 311. Germany Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 312. Germany Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. France Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 314. France Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 315. France Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 316. France Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 317. France Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 318. France Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 319. France Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 320. France Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 321. France Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 322. France Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 323. France Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 324. France Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 325. Russia Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 326. Russia Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 327. Russia Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 328. Russia Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 329. Russia Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 330. Russia Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 331. Russia Gadopentetate Dimeglumine Market Size, by Musculoskeletal System, 2017-2032 (USD Million)
TABLE 332. Russia Gadopentetate Dimeglumine Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 333. Russia Gadopentetate Dimeglumine Market Size, by End User, 2017-2032 (USD Million)
TABLE 334. Russia Gadopentetate Dimeglumine Market Size, by Diagnostic Centers, 2017-2032 (USD Million)
TABLE 335. Russia Gadopentetate Dimeglumine Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 336. Russia Gadopentetate Dimeglumine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 337. Italy Gadopentetate Dimeglumine Market Size, 2017-2032 (USD Million)
TABLE 338. Italy Gadopentetate Dimeglumine Market Size, by Form, 2017-2032 (USD Million)
TABLE 339. Italy Gadopentetate Dimeglumine Market Size, by Vials, 2017-2032 (USD Million)
TABLE 340. Italy Gadopentetate Dimeglumine Market Size, by Application, 2017-2032 (USD Million)
TABLE 341. Italy Gadopentetate Dimeglumine Market Size, by Cardiovascular System, 2017-2032 (USD Million)
TABLE 342. Italy Gadopentetate Dimeglumine Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 343. Italy Gadopentetate Dimeglumine

Companies Mentioned

  • Accord Healthcare Limited
  • Bayer AG
  • Beijing Beilu Pharmaceutical Co., Ltd.
  • Bracco Imaging S.p.A.
  • China National Pharmaceutical Group
  • Chongqing Pharmaceutical (Group) Co., Ltd.
  • Dr. Reddy's Laboratories Limited
  • GE HealthCare Technologies, Inc.
  • Guerbet S.A.
  • Hengrui Medicine Co., Ltd.
  • Jodas Expoim Pvt. Ltd.
  • Jubilant Pharmova Limited
  • Laksh Fine Chem Pvt. Ltd.
  • Lantheus Holdings, Inc.
  • Mallinckrodt plc
  • Sagent Pharmaceuticals, Inc.
  • Sanochemia Pharmazeutika AG
  • Shanghai Bracco Sine Pharmaceutical Corp., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

Related Topics

Related Reports

Gadopentetate Dimeglumine API Market - Global Forecast 2026-2032 - Product Image

Gadopentetate Dimeglumine API Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Gadolinium Contrast Media Market - Global Forecast 2026-2032 - Product Image

Gadolinium Contrast Media Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
MRI Contrast Media Market Report 2026 - Product Image

MRI Contrast Media Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Biological Imaging Reagents - Global Strategic Business Report - Product Image

Biological Imaging Reagents - Global Strategic Business Report

  • Report
  • 340 Pages
  • Global
From
Diagnostic Radiopharmaceuticals and Contrast Media - Global Strategic Business Report - Product Image

Diagnostic Radiopharmaceuticals and Contrast Media - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.